TICKERNERD
Menu
VSTMVSTMHealthcare · Biotechnology

VSTM Stock Forecast: Verastem, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$9.85
+0.82% on the day

The 10 Wall Street analysts covering Verastem, Inc. hold a median 12-month price target of $18 — +82.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 3 Nov 2026 — in the upper half.

Market cap
$1.2B
Ticker Nerd rank
66/ 100
Median analyst target
$18
Analysts covering
10
Revenue$40.1M+1775.4% y/y
Operating income−$32.7M
Net income−$34.7M
Free cash flow−$43.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.1%
1M
+27.9%
YTD
+27.6%
1Y
+24.5%
From 52W high
−7.4%
From 52W low
+185.5%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VSTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verastem, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
66/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Value
81
Volatility
76
Momentum
61
Accruals
58
Revisions
54
Size
42
Quality
40
Issuance
34

Growth (87): Sales and profits are climbing, and climbing faster than before.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VSTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VSTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26VSTMHigh $24Median $18Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $12Median $18High $24

The green dot is the last close — the median target sits +82.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
19 Oct 2026BTIGReiteratesBuy$24
16 Oct 2026MizuhoMaintainsOutperform$13 → $14
15 Oct 2026BTIGMaintainsBuy$18 → $24
15 Oct 2026JefferiesMaintainsBuy$11 → $13
15 Oct 2026RBC CapitalMaintainsOutperform$14 → $19
8 Oct 2026BTIGReiteratesBuy$18
8 Oct 2026BTIGReiteratesBuy—
5 Oct 2026BTIGReiteratesBuy—
5 Oct 2026BTIGReiteratesBuy$18
5 Oct 2026HC Wainwright & Co.ReiteratesBuy—
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$18
17 Sept 2026Wolfe ResearchInitiatesOutperform—
17 Sept 2026Wolfe ResearchInitiatesOutperform—
11 Sept 2026BTIGReiteratesBuy—
11 Sept 2026BTIGReiteratesBuy$18
11 Sept 2026HC Wainwright & Co.ReiteratesBuy—
11 Sept 2026HC Wainwright & Co.ReiteratesBuy$18
11 Aug 2026MizuhoMaintainsOutperform—
11 Aug 2026MizuhoMaintainsOutperform$14 → $13
7 Aug 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VSTM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VSTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Verastem, Inc. returned +24.5% against +12.9% for the S&P 500, dividends included.

VSTM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26VSTMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VSTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Verastem, Inc. (VSTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
13.5×

Cheaper than 11% of US stocks

Price / book
17.7×

Cheaper than 5% of US stocks

EV / EBITDA
−5.2×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
1775.4%

Higher than 99% of US stocks

Earnings growth (YoY)
1775.4%

Higher than 98% of US stocks

Gross margin
89.9%

Higher than 96% of US stocks

Operating margin
−81.6%

Higher than 15% of US stocks

Net margin
−231.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−471.2%

Higher than 3% of US stocks

Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Verastem, Inc. (VSTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Verastem, Inc. has a market value of $1.2B and an enterprise value of $831.0M.

  • Revenue in the twelve months to 30 June 2026: $87.5M. The latest quarter grew 1775.4% year on year.

  • Net income over the same four quarters: −$202.7M, a −231.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$171.8M.

  • Shares outstanding: 90.5M.

  • Trailing P/E: −3.2×; forward P/E: −8.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Verastem, Inc. employs 102 people — $858K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

VSTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VSTMVerastem, Inc.$1.2B66
AVLNAvalyn Pharma, Inc.$1.2B1
INBXInhibrx Biosciences, Inc.$1.2B25
VORVor Biopharma, Inc.$1.2B24
RAPPRapport Therapeutics, Inc.$1.2B52
MNKDMannKind Corp.$1.1B36
SGPSpyGlass Pharma, Inc.$1.1B2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verastem, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VSTM news & analysis

Verastem Oncology to Participate in Upcoming November Investor Conferences

Business Wire · 2 Nov 2026neutral

Verastem Oncology said its management team is scheduled to present at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9 and the Wolfe Research Healthcare Conference in New York City on November 10. The excerpt also begins listing a Jefferies London Healthcare Conference, but its details are cut off.

Why it matters — The scheduled appearances give VSTM watchers dates and venues for upcoming management presentations.

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

Business Wire · 22 Oct 2026neutral

Verastem Oncology announced it will host a conference call and webcast on November 5, 2026, at 4:30 p.m. ET, to discuss its third-quarter 2026 financial results and business updates. A live audio webcast and accompanying slides will be available under “Events & Presentations.”

Why it matters — VSTM watchers can use the scheduled event to hear the company’s quarterly results and business updates.

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Seeking Alpha · 14 Oct 2026neutral

The headline describes a transcript in which Verastem discusses new clinical data for its VS-7375 KRAS G12D inhibitor in pancreatic, lung, and colorectal cancers. The excerpt provides no further details about the data.

Why it matters — VSTM watchers may be interested in updates on the clinical development of VS-7375 across these cancer types.

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

MarketBeat · 14 Oct 2026positive

Verastem presented updated clinical data for its oral KRAS G12D inhibitor VS-7375 from the ongoing TARGET-D 101 study, which includes patients with pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. The company also outlined plans for registrational Phase II studies and frontline Phase III trials.

Why it matters — The update describes VS-7375's clinical development and Verastem's planned next steps, including trials in pancreatic cancer.

FAQ

Frequently asked questions about VSTM stock

What is the VSTM stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Verastem, Inc. have a median 12-month price target of $18, with estimates ranging from $12 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VSTM stock a buy right now?

Of the 10 analysts covering Verastem, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verastem, Inc. 66 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VSTM?

As at 3 Nov 2026, Verastem, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will VSTM stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +82.7% from the last close, and Ticker Nerd's factor model ranks Verastem, Inc. 66 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VSTM stock forecast for 2030?

No analyst covering Verastem, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VSTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $24 over the next 12 months.

How has VSTM stock performed over the past year?

Verastem, Inc. returned +24.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verastem, Inc. do?

Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway.

What is the latest news on VSTM?

The most recent item we track (Business Wire, 2 Nov 2026): "Verastem Oncology to Participate in Upcoming November Investor Conferences". Verastem Oncology said its management team is scheduled to present at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9 and the Wolfe Research Healthcare Conference in New York City on November 10. The excerpt also begins listing a Jefferies London Healthcare Conference, but its details are cut off.

Company

About Verastem, Inc.

Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway. Verastem Oncology’s current portfolio includes marketed and investigational therapies designed to address difficult-to-treat cancers, including rare ovarian cancer and other solid tumors. The company’s product and pipeline programs center on small-molecule oncology treatments such as RAF/MEK and FAK pathway inhibitors, reflecting a targeted approach to tumor biology. Verastem also works with companion diagnostics and clinical collaborations to support patient selection and study combination regimens. Based in Needham, Massachusetts, Verastem serves the oncology market by advancing therapies intended to improve treatment options across specialized cancer indications.

CEO Mr. Daniel W. Paterson · 102 employees · United States · https://www.verastem.com